Technology, Healthcare, Automotive Feb 22, 2022 04:59 PM (GMT+8) · EqualOcean
Chengda biology announced that the board of directors agreed that the company would transfer the assets and liabilities related to Benxi human vaccine business to Chengda Biology (Benxi) Co., Ltd., a wholly-owned subsidiary, according to the net book value on January 31, 2022; At the same time, the implementation subject of the raised investment project "human vaccine phase I construction project of Benxi Branch of Liaoning Chengda biology Co., Ltd." was changed from "Benxi Branch of Chengda biology" to "Benxi subsidiary".
Related companies: